PROCROP SIGNED
Professional cross-priming for ovary and prostate cancer
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0PROCROP project word cloud
Explore the words cloud of the PROCROP project. It provides you a very rough idea of what is the project "PROCROP" about.
Project "PROCROP" data sheet
The following table provides information about the project.
| Coordinator |
FUNDACION PARA LA INVESTIGACION MEDICA APLICADA FIMA
Organization address contact info |
| Coordinator Country | Spain [ES] |
| Project website | http://www.procrop.eu |
| Total cost | 7˙572˙500 € |
| EC max contribution | 5˙750˙000 € (76%) |
| Programme |
1. H2020-EU.3.1.3. (Treating and managing disease) |
| Code Call | H2020-PHC-2014-two-stage |
| Funding Scheme | RIA |
| Starting year | 2015 |
| Duration (year-month-day) | from 2015-09-01 to 2020-08-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | FUNDACION PARA LA INVESTIGACION MEDICA APLICADA FIMA | ES (PAMPLONA) | coordinator | 1˙190˙000.00 |
| 2 | STICHTING KATHOLIEKE UNIVERSITEIT | NL (NIJMEGEN) | participant | 1˙510˙000.00 |
| 3 | MILTENYI BIOTEC GMBH | DE (BERGISH GLADBACH) | participant | 1˙345˙000.00 |
| 4 | UNIVERSIDAD DE NAVARRA | ES (PAMPLONA) | participant | 1˙050˙000.00 |
| 5 | CENTRO NACIONAL DE INVESTIGACIONESCARDIOVASCULARES CARLOS III (F.S.P.) | ES (MADRID) | participant | 655˙000.00 |
| 6 | CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS | CH (LAUSANNE) | participant | 0.00 |
| 7 | UNIVERSITE DE LAUSANNE | CH (LAUSANNE) | participant | 0.00 |
Map
Project objective
Immune responses are initiated by antigen presentation mediated by dendritic cells (DC). There is a minority subset of DC highly specialised in starting up cytotoxic T lymphocytes able to kill tumor cells. PROCROP aims to develop in three pilot clinical trials a suitable individualized cancer vaccine technology for castration resistant prostate cancer and metastatic cancer of the ovary that would complement currently available therapies to increase efficacy. The project applies recent compelling knowledge on the identity of the main antigen-presenting DC subsets for vaccine elicitation of cytotoxic T lymphocytes endowed with the ability to seek and destroy tumour cells (such immune mechanism is termed crosspriming). This unique opportunity for superior DCs for immunotherapy comes from the fact that Miltenyi, a successful European biotech company, has the necessary proprietary reagents (anti-BDCA-3 monoclonal antibody and immunomagnetic selection technology), as well as the expertise to clinically develop a strategy of DC isolation and short-term cell culture for immunotherapy. From the point of view of the tumor antigens, processed autologous tumor material will be mixed with defined common tumor antigens in the form of recombinant proteins. This novel combination will permit stronger and broader antitumor immune responses and more accurate monitoring of the ensuing immunity against the tumors. These features should make the novel DC vaccine more efficacious than the currently US-approved DC vaccine PROVENGE and other DCs preparations undergoing trials, such as those derived from monocytes. Three of the leading groups in immunotherapy of cancer in Europe would join forces to develop this individualized cell therapy technology in clinical trials for two highly prevalent and unsatisfactorily managed malignant conditions. Industrial partnership provides the unique advantage of producing a rigorously standardized product for eventual multicentre trials.
Deliverables
| PROCROP Logo, graphical Chart and webpage | Websites, patent fillings, videos etc. | 2020-02-24 12:20:07 |
Take a look to the deliverables list in detail: detailed list of PROCROP deliverables.
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2017 |
Arantza Azpilikueta, Elixabet Bolaños, Valerie Lang, Sara Labiano, Maria A. Aznar, Iñaki Etxeberria, Alvaro Teijeira, Maria E. Rodriguez-Ruiz, Jose L. Perez-Gracia, Maria Jure-Kunkel, Juan M. Zapata, Manuel S. Rodriguez, Ignacio Melero Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4–1BB) published pages: e1368605, ISSN: 2162-402X, DOI: 10.1080/2162402X.2017.1368605 |
OncoImmunology 7/1 | 2020-02-24 |
| 2018 |
Carlos del Fresno, Salvador Iborra, Paula Saz-Leal, MarÃa MartÃnez-López, David Sancho Flexible Signaling of Myeloid C-Type Lectin Receptors in Immunity and Inflammation published pages: , ISSN: 1664-3224, DOI: 10.3389/fimmu.2018.00804 |
Frontiers in Immunology 9 | 2020-02-24 |
| 2018 |
Maria M. M. Kaisar, Manuel Ritter, Carlos del Fresno, Hulda S. Jónasdóttir, Alwin J. van der Ham, Leonard R. Pelgrom, Gabriele Schramm, Laura E. Layland, David Sancho, Clarissa Prazeres da Costa, Martin Giera, Maria Yazdanbakhsh, Bart Everts Dectin-1/2–induced autocrine PGE2 signaling licenses dendritic cells to prime Th2 responses published pages: e2005504, ISSN: 1545-7885, DOI: 10.1371/journal.pbio.2005504 |
PLOS Biology 16/4 | 2020-02-24 |
| 2018 |
Christina Wefers, Tjitske Duiveman-de Boer, Petra Zusterzeel, Leon Massuger, David Fuchs, Ruurd Torensma, Craig Wheelock, I. de Vries Different Lipid Regulation in Ovarian Cancer: Inhibition of the Immune System published pages: 273, ISSN: 1422-0067, DOI: 10.3390/ijms19010273 |
International Journal of Molecular Sciences 19/1 | 2020-02-24 |
| 2018 |
Christina Wefers, Gerty Schreibelt, Leon F. A. G. Massuger, I. Jolanda M. de Vries, Ruurd Torensma Immune Curbing of Cancer Stem Cells by CTLs Directed to NANOG published pages: , ISSN: 1664-3224, DOI: 10.3389/fimmu.2018.01412 |
Frontiers in Immunology 9 | 2020-02-24 |
| 2017 |
David Sancho, Michel Enamorado, Johan Garaude Innate Immune Function of Mitochondrial Metabolism published pages: , ISSN: 1664-3224, DOI: 10.3389/fimmu.2017.00527 |
Frontiers in Immunology 8 | 2020-02-24 |
| 2017 |
Michel Enamorado, Salvador Iborra, Elena Priego, Francisco J. Cueto, Juan A. Quintana, Sarai MartÃnez-Cano, Ernesto MejÃas-Pérez, Mariano Esteban, Ignacio Melero, Andrés Hidalgo, David Sancho Enhanced anti-tumour immunity requires the interplay between resident and circulating memory CD8+ T cells published pages: 16073, ISSN: 2041-1723, DOI: 10.1038/ncomms16073 |
Nature Communications 8 | 2020-02-24 |
| 2017 |
Marcos Vasquez, Vladimir Paredes-Cervantes, Fernando Aranda, Nuria Ardaiz, Celia Gomar, Pedro Berraondo Antitumor effect of an adeno-associated virus expressing apolipoprotein A-1 fused to interferon alpha in an interferon alpha-resistant murine tumor model published pages: , ISSN: 1949-2553, DOI: 10.18632/oncotarget.14127 |
Oncotarget 8/3 | 2020-02-24 |
| 2016 |
A. R. Sanchez-Paulete, F. J. Cueto, M. Martinez-Lopez, S. Labiano, A. Morales-Kastresana, M. E. Rodriguez-Ruiz, M. Jure-Kunkel, A. Azpilikueta, M. A. Aznar, J. I. Quetglas, D. Sancho, I. Melero Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells published pages: 71-79, ISSN: 2159-8274, DOI: 10.1158/2159-8290.CD-15-0510 |
Cancer Discovery 6/1 | 2020-02-24 |
| 2016 |
Johan Garaude, Rebeca AcÃn-Pérez, Sarai MartÃnez-Cano, Michel Enamorado, Matteo Ugolini, Estanislao Nistal-Villán, Sandra Hervás-Stubbs, Pablo PelegrÃn, Leif E Sander, José A EnrÃquez, David Sancho Mitochondrial respiratory-chain adaptations in macrophages contribute to antibacterial host defense published pages: 1037-1045, ISSN: 1529-2908, DOI: 10.1038/ni.3509 |
Nature Immunology 17/9 | 2020-02-24 |
| 2016 |
Bettina Weigelin, Elixabet Bolaños, Maria E. Rodriguez-Ruiz, Ivan Martinez-Forero, Peter Friedl, Ignacio Melero Anti-CD137 monoclonal antibodies and adoptive T cell therapy: a perfect marriage? published pages: 493-497, ISSN: 0340-7004, DOI: 10.1007/s00262-016-1818-5 |
Cancer Immunology, Immunotherapy 65/5 | 2020-02-24 |
| 2016 |
Marcos Vasquez, Jessica Fioravanti, Fernando Aranda, Vladimir Paredes, Celia Gomar, Nuria Ardaiz, Veronica Fernandez-Ruiz, Miriam Méndez, Estanislao Nistal-Villan, Esther Larrea, Qinshan Gao, Gloria Gonzalez-Aseguinolaza, Jesus Prieto, Pedro Berraondo Interferon alpha bioactivity critically depends on Scavenger receptor class B type I function published pages: e1196309, ISSN: 2162-402X, DOI: 10.1080/2162402X.2016.1196309 |
OncoImmunology 5/8 | 2020-02-24 |
| 2016 |
I. Melero, P. Berraondo, M. E. Rodriguez-Ruiz, J. L. Perez-Gracia Making the Most of Cancer Surgery with Neoadjuvant Immunotherapy published pages: 1312-1314, ISSN: 2159-8274, DOI: 10.1158/2159-8290.CD-16-1109 |
Cancer Discovery 6/12 | 2020-02-24 |
| 2017 |
Till S.M. Mathan, Johannes Textor, Annette E. Sköld, Inge Reinieren-Beeren, Tom van Oorschot, Mareke Brüning, Carl G. Figdor, Sonja I. Buschow, Ghaith Bakdash, I. Jolanda M. de Vries Harnessing RNA sequencing for global, unbiased evaluation of two new adjuvants for dendritic-cell immunotherapy published pages: , ISSN: 1949-2553, DOI: 10.18632/oncotarget.15190 |
Oncotarget | 2020-02-24 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PROCROP" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "PROCROP" are provided by the European Opendata Portal: CORDIS opendata.
More projects from the same programme (H2020-EU.3.1.3.)
HELP (2019)
Collaboration for innovation: Establishment of a pan-nematode drug development platform
Read MoreAutoCRAT (2020)
Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis
Read MoreTT4CL (2019)
Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis
Read More